JCEM: Risk factors for severe hypophosphatemia after carboxymaltose iron treatment

Hypophosphatemia, osteomalacia, and fractures are some complications of intravenous iron
.

Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.

The researchers conducted a secondary analysis of the PHOPHARE-IDA randomized clinical trial
.

The study was based on 30 outpatient clinics in the United States and included 245 iron-deficiency anemia patients 18 years of age and older

Vitamin D

FCM is the only consistent risk factor for hypophosphatemia (<2.
0mg/dl; ratio to FDI: 38.
37; 95% confidence interval [CI]: 16.
62-88.
56; p<0.
001)
.

Only patients treated with FCM had severe hypophosphatemia (<1.

More severe hypophosphatemia was associated with a significant increase in iFGF23, PTH, and alkaline phosphatase, and a more severe decrease in 1,25(OH)2D and ionized calcium (all p<0.
05)
.

The changes in the levels of iFGF23, PTH, 1,25(OH)2D, and N-terminal procollagen-1 peptide in patients with persistent hypophosphatemia and regression hypophosphatemia were significantly greater (all p<0.

Thus, FCM treatment is the only consistent risk factor for hypophosphatemia
.

Patients with severe or persistent hypophosphatemia after FCM treatment are accompanied by more severe bone and mineral metabolism disorders

FCM treatment is the only consistent risk factor for hypophosphatemia

Original source:

Benedikt Schaefer.

Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose in this message